Structure Therapeutics Inc.
GPCR
$54.51
-$0.19-0.35%
NASDAQ
| 06/30/2026 | 03/31/2026 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | -18.80% | 30.17% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 32.73% | 750.50% | |||
| Operating Income | -32.73% | -750.50% | |||
| Income Before Tax | -39.78% | -328.43% | |||
| Income Tax Expenses | 23.16% | 11.76% | |||
| Earnings from Continuing Operations | -39.74% | -330.18% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -39.74% | -330.18% | |||
| EBIT | -32.73% | -750.50% | |||
| EBITDA | -32.96% | -713.47% | |||
| EPS Basic | -39.33% | -301.44% | |||
| Normalized Basic EPS | -39.37% | -285.48% | |||
| EPS Diluted | -39.33% | -301.44% | |||
| Normalized Diluted EPS | -39.37% | -285.48% | |||
| Average Basic Shares Outstanding | 0.29% | 14.27% | |||
| Average Diluted Shares Outstanding | 0.29% | 14.27% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||